Last reviewed · How we verify
HRS-9190
At a glance
| Generic name | HRS-9190 |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study on the Mass Balance of [14C]HRS-9190 for Injection in Healthy Participants (PHASE1)
- Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults (PHASE2)
- A Study to Evaluate the Safety, Tolerability and Dose-Response Relationship of HRS-9190 in Healthy Subjects (PHASE1)
- Safety and Efficacy of HRS-9190 Compared to Cisatracurium for Continuous Intravenous Infusion in Adults (PHASE2)
- Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults (PHASE2)
- A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HRS-9190 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRS-9190 CI brief — competitive landscape report
- HRS-9190 updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI